Earnings summaries and quarterly performance for Waystar Holding.
Executive leadership at Waystar Holding.
Matthew Hawkins
Chief Executive Officer
Christopher Schremser
Chief Technology Officer
Eric Sinclair
Chief Business Officer
Greg Packer
Chief Legal Officer and Secretary
Kim Wittman
Chief People Officer
Missy Miller
Chief Marketing Officer
Steven Oreskovich
Chief Financial Officer
T. Craig Bridge
Chief Transformation Officer
Board of directors at Waystar Holding.
Aashima Gupta
Director
Eric Liu
Director
Ethan Waxman
Director
Heidi Miller
Director
John Driscoll
Chair of the Board
Lauren Young
Director
Michael Roman
Director
Paul Moskowitz
Director
Priscilla Hung
Director
Robert DeMichiei
Director
Samuel Blaichman
Director
Vivian Riefberg
Director
Research analysts who have asked questions during Waystar Holding earnings calls.
Adam Hotchkiss
Goldman Sachs
4 questions for WAY
Elizabeth Anderson
Evercore ISI
4 questions for WAY
Richard Close
Canaccord Genuity Group
4 questions for WAY
Allen Lutz
Bank of America
3 questions for WAY
Brian Peterson
Raymond James Financial
3 questions for WAY
George Hill
Deutsche Bank
3 questions for WAY
Ryan Daniels
William Blair & Company, L.L.C.
3 questions for WAY
Anne McCormick
JPMorgan Chase & Co.
2 questions for WAY
Jailendra Singh
Truist Securities
2 questions for WAY
Saket Kalia
Barclays Capital
2 questions for WAY
Alex L. Gogelov
JPMorgan Chase & Co.
1 question for WAY
Anne Samuel
JPMorgan Chase & Co.
1 question for WAY
Brian Tanquilut
Jefferies
1 question for WAY
Charles Rhyee
TD Cowen
1 question for WAY
Daniel Grosslight
Citigroup
1 question for WAY
Jared Haase
William Blair & Company
1 question for WAY
Johnathan McCary
Raymond James
1 question for WAY
Liz Lee
Deutsche Bank
1 question for WAY
Sean Dodge
RBC Capital Markets
1 question for WAY
Stephanie Davis
Barclays
1 question for WAY
Steven Valiquette
Mizuho
1 question for WAY
Recent press releases and 8-K filings for WAY.
- Waystar's core business helps healthcare providers ensure efficient payment, achieving a 99% first pass clean claim rate and differentiating through a platform approach that demonstrates clear ROI.
- The company's revenue is split approximately 50% subscription and 50% volume-based, benefiting from strong utilization observed over the past five to six quarters.
- Generative AI solutions have delivered significant results, with clients reporting a 70% decrease in time for prior authorizations and a 90% decrease in time for denials and appeals management, with monetization through price increases and new SKUs.
- The $1.25 billion acquisition of Iodine strategically expanded Waystar into clinical documentation, integrating over 160 AI models to enhance claim accuracy.
- Waystar maintains long-term targets of low double-digit revenue growth, 40%+ Adjusted EBITDA margins, and 70%+ free cash flow conversion, alongside an annual deleveraging goal of one turn.
- Waystar acquired Iodine for $1.25 billion, integrating its 160+ AI modules to enhance clinical documentation and advance its "perfect undeniable claim" vision.
- New generative AI products, part of the Altitude suite, are showing strong results, with clients reporting a 70% decrease in prior authorization time and a 90% decrease in denials and appeals management time, contributing to a growing portion of the company's pipeline and bookings.
- The company's revenue mix is approximately 50% subscription and 50% volume-based, with a strong net revenue retention rate of 108-110%, supported by 97% gross revenue retention and 3-4% annual price increases.
- Waystar differentiates itself through its platform approach, demonstrated ROI, a database of over 6 billion annual transactions for AI learning, and extensive connectivity with over 500 EHR/practice management systems and thousands of payers.
- For FY 2025, the guide implies an 8% year-over-year standalone growth rate in Q4, with long-term targets including low double-digit revenue growth, 40%+ adjusted EBITDA margins, and 70%+ free cash flow conversion.
- Waystar's core business focuses on helping healthcare providers efficiently capture revenue, achieving a 99% first pass clean claim rate for its clients, significantly higher than the national average denial rate of 16-17%.
- The company's $1.25 billion acquisition of Iodine has expanded its platform into clinical documentation, integrating over 160 AI models to convert unstructured clinical notes into structured information for claims and improve prior authorizations.
- Waystar's generative AI solutions have demonstrated substantial efficiency gains, including a 70% decrease in time for prior authorizations and a 90% decrease in time for denials and appeals management.
- The revenue mix is approximately 50% subscription and 50% volume-based, with the company reporting strong utilization over the past five to six quarters. Waystar targets low double-digit revenue growth and a net revenue retention rate of 108-110%.
- Waystar maintains a competitive advantage through its large database of over 6 billion annual transactions for AI model training and extensive connectivity with over 500 EHR/practice management systems and thousands of payers.
- Waystar reported strong Q3 2025 financial results, with revenue growing 12% year-over-year to $269 million and adjusted EBITDA increasing 17% year-over-year to $113 million, achieving a 42% adjusted EBITDA margin.
- The company completed the acquisition of Iodine Software on October 1, which is expected to expand its total addressable market by over 15% and contribute approximately $30 million in revenue in Q4 2025.
- Waystar raised its full-year 2025 guidance, with revenue now expected to be between $1,085 million and $1,093 million (midpoint $1,089 million) and adjusted EBITDA between $451 million and $455 million (midpoint $453 million), reflecting a 15% year-over-year revenue growth rate and an adjusted EBITDA margin of approximately 42%.
- The company's net revenue retention rate was 113% for the last 12 months, and unleveraged free cash flow for Q3 2025 was $96 million.
- Waystar reported strong financial results for Q3 2025, with revenue growing 12% year-over-year to $269 million and an adjusted EBITDA margin of 42%.
- The company completed the acquisition of Iodine Software on October 1, which expands its total addressable market by more than 15% and adds nearly 150 health systems to its client base.
- Waystar raised its full-year 2025 guidance, projecting revenue between $1,085 million and $1,093 million (midpoint $1,089 million) and adjusted EBITDA between $451 million and $455 million (midpoint $453 million), with an expected 42% adjusted EBITDA margin.
- The Net Revenue Retention Rate (NRR) was 113% for the last 12 months, and the number of clients generating over $100,000 in trailing 12-month revenue increased 11% year-over-year to 1,306 in Q3.
- Waystar achieved $269 million in revenue for Q3 2025, representing 12% year-over-year growth, and an adjusted EBITDA of $113 million, resulting in a 42% adjusted EBITDA margin.
- The company completed the acquisition of Iodine Software on October 1, 2025, which is expected to expand its total addressable market by more than 15% and accelerate its product roadmap by nearly two years.
- Client metrics remained robust, with a Net Revenue Retention Rate of 113% for the last 12 months and an 11% year-over-year increase in clients generating over $100,000 in trailing 12-month revenue, reaching 1,306 in Q3 2025.
- Waystar raised its full-year 2025 guidance, projecting revenue between $1,085 million and $1,093 million (midpoint $1,089 million) and adjusted EBITDA between $451 million and $455 million (midpoint $453 million), with an expected adjusted EBITDA margin of approximately 42%.
- Waystar reported strong Q3 2025 performance, with 12% revenue growth and 17% Adjusted EBITDA growth compared to Q3 2024, achieving an Adjusted EBITDA margin of 42%.
- The company generated $96 million in unlevered free cash flow for Q3 2025.
- For the twelve months ended September 30, 2025, Waystar saw 11% year-over-year growth in clients with over $100,000 in TTM revenue and a net revenue retention rate of 113%.
- Waystar raised its FY 2025 guidance midpoints, projecting revenue of $1,089 million and Adjusted EBITDA of $453 million, which includes $30 million in revenue and $12 million in Adjusted EBITDA from the lodine Software acquisition for one full quarter.
- Waystar Holding Corp. reported Q3 2025 revenue of $268.7 million, representing a 12% year-over-year increase.
- For Q3 2025, the company achieved net income of $30.6 million and non-GAAP net income of $67.8 million, alongside an adjusted EBITDA of $112.7 million and a 42% adjusted EBITDA margin.
- The company is raising its full fiscal year 2025 guidance, with total revenue now expected to be between $1.085 billion and $1.093 billion and adjusted EBITDA between $451 million and $455 million.
- CEO Matt Hawkins stated that Waystar delivered "another quarter of double-digit revenue growth and strong margins, outpacing our guidance on both measures," and highlighted the ongoing integration of Iodine Software to enhance its AI-powered platform.
- Waystar reported revenue of $268.7 million for Q3 2025, marking a 12% year-over-year increase, with net income of $30.6 million and non-GAAP net income of $67.8 million.
- The company achieved a net income margin of 11% and an adjusted EBITDA margin of 42% in the third quarter of 2025.
- Waystar is raising its full fiscal year 2025 guidance, with total revenue now expected to be between $1.085 billion and $1.093 billion, and adjusted EBITDA projected to be between $451 million and $455 million.
- CEO Matt Hawkins noted double-digit revenue growth and strong margins, attributing confidence in the raised full-year guidance to continuing demand and focused execution, including the integration of Iodine Software.
- Waystar Holding Corp. completed the acquisition of Iodine Software on October 1, 2025.
- The acquisition expands Waystar's total addressable market by over 15% and is expected to be immediately accretive to gross margin and adjusted EBITDA margin.
- The acquisition is also anticipated to be accretive to revenue growth and non-GAAP net income per diluted share in 2027.
- The consideration for the acquisition was approximately $458,598,269.88 in cash and 16,639,906 shares of Waystar Common Stock, with each share valued at $37.31.
Quarterly earnings call transcripts for Waystar Holding.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Waystar Holding's earnings for you
Get instant analysis when filings drop